Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Barrier Extreme is a topical skin repair formulation developed through a collaboration between West China Hospital, Sichuan University, and Yunnan Botanee Bio-Technology Group. It is specifically indicated for the management of sensitive skin, acne, and rosacea. The product's mechanism of action involves the restoration of the skin's lipid barrier and the reduction of neurogenic inflammation. Key active ingredients include *Portulaca oleracea* extract, which acts as an antagonist to the TRPV1 receptor to alleviate itching and burning sensations, and *Prinsepia utilis* oil, which provides essential fatty acids to repair the stratum corneum. Clinical studies conducted at West China Hospital have demonstrated its efficacy as both a standalone treatment and an adjuvant therapy to reduce the side effects of topical medications and laser procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Barrier Extreme.